Rare diseases
Investigational molecules
Locations
Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study
ItalyA Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease
ItalyEfficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)
ItalyINCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
ItalyVMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk
ItalyBMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer
ItalyNipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
ItalyJNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments
ItalyNHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients
ItalyEIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors
ItalyStudy of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
ItalyA study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
